Blue Earth Diagnostics, a leading molecular imaging company, will be presenting its latest findings on POSLUMA (Flotufolastat F 18) at the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in Washington, DC, from September 29 to October 2, 2024.
## POSLUMA: A Breakthrough in Prostate Cancer Imaging
**POSLUMA** is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It is specifically used in patients with suspected metastasis or recurrence based on elevated serum prostate-specific antigen (PSA) levels.
### Highlighting POSLUMA at ASTRO 2024
Blue Earth Diagnostics is set to make significant contributions to the ASTRO 2024 Annual Meeting with presentations and an Industry-Expert Theater event:
#### Presentation of SPOTLIGHT Study Results
The company will present additional results from the completed Phase 3 SPOTLIGHT study, a pivotal trial that evaluated the efficacy and safety of POSLUMA in men with recurrent prostate cancer.
#### Investigator-Initiated Study Presentation
An investigator-initiated study exploring the combined use of POSLUMA PET and MRI in recurrent prostate cancer will also be presented, highlighting the potential of this dual imaging approach.
#### “Let’s Talk About POSLUMA” Industry-Expert Theater Event
Blue Earth Diagnostics will host an Industry-Expert Theater event titled “Let’s Talk About POSLUMA (Flotufolastat F 18).” This event will feature presentations by invited speakers:
* Sean Collins, MD, PhD
* Elizabeth Hawk, MS, MD, PhD, DABNM, DABR
The event will provide attendees with in-depth insights into the clinical applications of POSLUMA and its impact on prostate cancer management.
### Event Details:
* **Industry-Expert Theater Event:** Sunday, September 29, 2024, 12:00 PM – 1:00 PM ET, Theater 1, Walter E. Washington Convention Center
* **Medical Affairs Information Booth:** Throughout the ASTRO Annual Meeting
### Important Safety Information
* Image interpretation with POSLUMA PET requires careful consideration.
* A negative image does not definitively rule out the presence of prostate cancer.
* Conversely, a positive image does not confirm the presence of prostate cancer.
## Frequently Asked Questions (FAQs)
### What is POSLUMA, and how is it used?
POSLUMA is a radioactive diagnostic agent used in PET scans to detect prostate cancer cells. It targets PSMA, a protein found on the surface of prostate cancer cells.
### Who is eligible for a POSLUMA PET scan?
POSLUMA PET scans are typically recommended for men with suspected prostate cancer metastasis or recurrence, particularly those with elevated PSA levels.
### What can I expect during a POSLUMA PET scan?
During the scan, you will lie down on a table while a small amount of POSLUMA is injected into your vein. After a brief waiting period for the agent to circulate, the PET scanner will capture images of your body, highlighting areas where POSLUMA has accumulated.
### What are the benefits of using POSLUMA for prostate cancer imaging?
POSLUMA offers high sensitivity and specificity in detecting prostate cancer cells, enabling more accurate staging and localization of the disease. This information is crucial for guiding treatment decisions and improving patient outcomes.
### What are the potential side effects of POSLUMA?
POSLUMA is generally safe and well-tolerated. Common side effects are usually mild and may include injection site reactions, headache, and fatigue.
## Conclusion
Blue Earth Diagnostics’ participation at the ASTRO 2024 Annual Meeting underscores its commitment to advancing prostate cancer diagnostics. The presentations and expert discussions surrounding POSLUMA will provide valuable insights for clinicians and researchers alike, ultimately contributing to improved patient care.
_Source: Biospace_